Atomo Diagnostics Expands HIV Self-Test Market and Secures Syphilis Test License

Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.

Atomo Diagnostics Ltd. has reported significant growth in its HIV Self-Test business, highlighted by a $230k order for the national scale-up of the CONNECT Programme in Australia and a product launch in New Zealand through Chemist Warehouse. The company also secured an exclusive license for a novel syphilis test, supported by a $2.44 million grant from the Commonwealth Government, which will aid in further analytical testing and commercial discussions.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and supply of rapid diagnostic test devices. The company is primarily known for its HIV Self-Test products and is expanding its market presence in developed regions, including Australia and New Zealand.

Average Trading Volume: 450,155

Technical Sentiment Signal: Buy

Current Market Cap: A$12.78M

For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.